Regular Article
P450-Catalyzed In-Chain Desaturation of Valproic Acid: Isoform Selectivity and Mechanism of Formation of Δ3-Valproic Acid Generated by Baculovirus- Expressed CYP3A1

https://doi.org/10.1006/abbi.1998.0742Get rights and content

Abstract

The mechanism of formation of the in-chain, unsaturated fatty acid metabolite, Δ3-valproic acid (Δ3-VPA) by rat liver microsomes was examined. Microsomal rates of formation of Δ3-VPA were below quantifiable limits in reactions catalyzed by control female rat liver microsomes, but were induced more than 20-fold following pretreatment with triacetyloleandomycin and pregnenolone-16α-carbonitrile. Microsomal incubations conducted with 3-hydroxy-VPA or [2-2H1]VPA demonstrated that Δ3-VPA did not arise by dehydration of preformed alcohol nor was it reversibly isomerized to Δ2-VPA. CYP3A1 expression was optimized in the baculovirus expression vector system, and infected insect cell membranes which were supplemented with P450 reductase catalyzed formation of 3-OH-, 4-OH-, 5-OH-, Δ3-, and Δ4-VPA in ratios of 160:35:6:3:1. Intramolecular deuterium isotope effects on metabolite formation, determined with cDNA-expressed CYP3A1 and either [3,3-2H2]VPA or [4,4-2H2]VPA, yieldedkH/kDvalues for Δ3-VPA of 2.00 ± 0.06 and 2.36 ± 0.08, respectively. These values were significantly lower than the isotope effects observed in the same incubations for 3-OH-VPA formation from 3,3-D2-VPA (kH/kD= 6.04 ± 0.08), or for 4-OH- and Δ4-VPA formation from 4,4-D2-VPA (kH/kD> 5). Collectively, these data demonstrate the existence of a microsomal P450-dependent in-chain fatty acid desaturase system distinct from the well-documented cytochromeb5-linked CoA desaturases and suggest further that CYP3A1-dependent formation of Δ3-VPA arises via nonselective, initial hydrogen atom abstraction from either the C-3 or the C-4 position.

References (41)

  • P.R. Ortiz de Montellano

    Trends Pharmacol. Sci.

    (1989)
  • N. Gerber et al.

    J. Pediatr.

    (1979)
  • A.E. Rettie et al.

    J. Biol. Chem.

    (1988)
  • M. Daujat et al.

    Methods Enzymol.

    (1991)
  • P.H. Roos et al.

    Biochem. Pharmacol.

    (1993)
  • M.R. Franklin

    Methods Enzymol.

    (1991)
  • A.J.M. Sadeque et al.

    Biochim. Biophys. Acta

    (1993)
  • X. Guan et al.

    Chem.-Biol. Interact.

    (1998)
  • M. Halvorson et al.

    Arch. Biochem. Biophys.

    (1990)
  • M.B. Telhada et al.

    Arch. Biochem. Biophys.

    (1992)
  • A. Mahnke et al.

    Arch. Biochem. Biophys.

    (1997)
  • K.S. Prickett et al.

    Biochem. Biophys. Res. Commun.

    (1984)
  • E.H. Oliw et al.

    Arch. Biochem. Biophys.

    (1987)
  • S.D. Nelson

    Drug Metab. Rev.

    (1995)
  • D.C. Dahlin et al.

    Proc. Natl. Acad. Sci. U.S.A.

    (1984)
  • G.L. Skiles et al.

    Chem. Res. Toxicol.

    (1996)
  • F.P. Guengerich et al.

    Chem. Res. Toxicol.

    (1991)
  • J. Bolton et al.

    Drug Metab. Dispos.

    (1991)
  • A.E. Rettie et al.

    Science

    (1987)
  • T.A. Baillie

    Chem. Res. Toxicol.

    (1988)
  • Cited by (0)

    1

    Present address: Molecular Biology Unit, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.

    2

    To whom correspondence should be addressed at Department of Medicinal Chemistry, University of Washington, Box 357610, Seattle, WA 98195. Fax: (206) 685-3252. E-mail:[email protected].

    View full text